Nama's AI scorecard currently rates Praxis Precision Medicines Sell (3.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does PRAX report earnings?

Praxis Precision Medicines's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$3.63.

What is the PRAX price target?

The median analyst price target from 21 analysts is $582.00, with a range of $188.00 – $1,201.00.

Is PRAX Shariah compliant?

Nama's AAOIFI-style screen reads Praxis Precision Medicines as Can't Tell. A figure the screen needs is missing, so it can't tell.

Nama Insights

Praxis Precision Medicines (PRAX)

Healthcare · Biotechnology · NASDAQ

Praxis Precision Medicines (PRAX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $7.75B and a free-cash-flow yield of -4.0%. Over the most recent reported fiscal year, revenue declined 100.0%. Nama's AI scorecard rates it Sell, 3.6 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Sell · 3.6/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Rising · +61.3% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Can't Tell

A figure the screen needs is missing, so it can't tell.

Off its high

-29.3%

How far the last close sits under the highest price of the past five years.

Market cap	$7.75B
Trailing P/E	—
Price / book	5.8
Price / sales	—
FCF yield	-4.0%
Dividend yield	—
Gross margin	0.0%
Operating margin	0.0%
Net margin	0.0%
Revenue growth (YoY)	-100.0%
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	2.8
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

PRAX earnings

Next report: Nov 9, 2026 (Q3 2026, EPS estimate -$3.63). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 6, 2026	-$2.87	-$3.69	+22.2%	$0
Q1 2026	May 7, 2026	-$3.20	-$3.68	+13.0%	$0
Q4 2025	Feb 19, 2026	-$3.50	-$3.13	-11.8%	$0
Q3 2025	Nov 5, 2025	-$3.36	-$3.49	+3.7%	$0

PRAX analyst price target

Median target $582.00 from 21 analysts, ranging $188.00 – $1,201.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live PRAX data on Nama Insights →

Recent Congressional trades

Praxis Precision Medicines trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Oct 12, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Sep 4, 2026

PRAX FAQ

Is PRAX a buy?: Nama's AI scorecard currently rates Praxis Precision Medicines Sell (3.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does PRAX report earnings?: Praxis Precision Medicines's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$3.63.
What is the PRAX price target?: The median analyst price target from 21 analysts is $582.00, with a range of $188.00 – $1,201.00.
Is PRAX Shariah compliant?: Nama's AAOIFI-style screen reads Praxis Precision Medicines as Can't Tell. A figure the screen needs is missing, so it can't tell.